Figure 6. Concurrent administration of ABL and ATR inhibitors synergistically inhibits SCLC growth and viability.

(A) H69 cells were treated with a range of ABL001 (0–16 μM) and ATR inhibitor M6620 (0–9.6 μM); alone or in combination for 72 h; DMS53 cells were treated with a range of GMB475 (0–3 μM) and M6620 (0–0.3 μM) alone or in combination for 72 h. Cell viability and growth were measured using Cell-Titer-Glo. Data were analyzed using Synergy Finder presented by Bliss and HSA analysis (score >10 is synergistic). P values for significance are indicated in the graph.

(B) H69 cells were treated with ABL001 (4 μM) and M6620 (2.4 μM) for 72 h; DMS53 cells were treated with GMB475 (3 μM) and M6620 (0.3 μM) for 72 h. Cell viability and growth was measured by Cell-titer-Glo. Data (represented as mean +/− SEM) were plotted with GraphPad Prism. Statistics was performed with a one-way ANOVA: ***p < 0.001 and ****p < 0.0001.

(C) H69 cells were treated with ABL001 (6 μM) and M6620 (2 μM).

(D) DMS53 cells were treated with GMB475 (5 μM) and M6620 (1.2 μM) for 48 h. Total cell lysates were analyzed for the indicated proteins by western blotting. (Cl-PARP: Cleaved PARP; Cl-Caspase 3: Cleaved caspase 3).

(E) H69 cells were treated with ABL001 (7.5 μM) and M6620 (0.75 μM).

(F) DMS53 cells were treated with GMB475 (3 μM) and M6620 (0.3 μM) for 72 h. Total cell lysates were analyzed for the indicated proteins by western blotting.